CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 119 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,900 | +192.2% | 501 | +77.0% | 0.00% | – |
| Q2 2023 | $5,100 | +6.6% | 283 | -5.0% | 0.00% | – |
| Q1 2023 | $4,786 | -10.1% | 298 | +2.4% | 0.00% | – |
| Q4 2022 | $5,325 | -33.4% | 291 | -26.7% | 0.00% | – |
| Q3 2022 | $8,000 | +60.0% | 397 | +40.3% | 0.00% | – |
| Q2 2022 | $5,000 | -16.7% | 283 | 0.0% | 0.00% | – |
| Q1 2022 | $6,000 | -33.3% | 283 | -11.8% | 0.00% | – |
| Q4 2021 | $9,000 | +28.6% | 321 | 0.0% | 0.00% | – |
| Q3 2021 | $7,000 | +40.0% | 321 | +13.4% | 0.00% | – |
| Q2 2021 | $5,000 | +25.0% | 283 | 0.0% | 0.00% | – |
| Q1 2021 | $4,000 | 0.0% | 283 | 0.0% | 0.00% | – |
| Q4 2020 | $4,000 | – | 283 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 3,375,169 | $84,379,000 | 7.91% |
| RA Capital Management | 1,875,209 | $46,880,000 | 2.52% |
| Perceptive Advisors | 2,587,953 | $64,698,000 | 1.48% |
| New Leaf Venture Partners, L.L.C. | 167,700 | $4,193,000 | 1.12% |
| Orbimed Advisors | 2,039,282 | $50,982,000 | 0.79% |
| Eventide Asset Management | 803,839 | $20,096,000 | 0.61% |
| Novo Holdings A/S | 135,009 | $3,375,000 | 0.47% |
| Opaleye Management Inc. | 36,000 | $900,000 | 0.27% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 490,000 | $12,250,000 | 0.03% |
| Baker Brothers Advisors | 132,985 | $3,325,000 | 0.02% |